CCL2 promotes metastasis and epithelial–mesenchymal transition of non‐small cell lung cancer via PI3K /Akt/ mTOR and autophagy pathways
Cell Proliferation · 2024-03 · 57 (3)
DOI: 10.1111/cpr.13560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 18.10.2023. Verfasst von Hui Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital of Dalian Medica…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In non‐small cell lung cancer (NSCLC), metastasis is the most common phenotype, and autophagy plays a vital role in its regulation. However, there are limited data on how autophagy‐related genes and metastasis‐related genes affect NSCLC progression. Our goal was to identify the genes that regulate autophagy and metastasis in NSCLC, and to assess the underlying mechanisms in this current study. RNA sequencing data from public databases were used to screen differentially expressed autophagy‐ and metastasis‐associated genes. Enrichment analyses and immune correlations were conducted to identify hub genes and potential regulating pathways in NSCLC. In this study, we found that CCL2 expression was highly expressed in NSCLC tissues and high CCL2 level was correlated with strong infiltration in lung tissues from NSCLC patients. Overexpression of CCL2 can enhance the metastasis of NSCLC cells in nude mice. Furthermore, CCL2 activated the PI3K/Akt/mTOR signalling pathway axis, promoted epithelial–mesenchymal transition (EMT), and blocked the autophagic flux in NSCLC cells. Therefore, our results indicate that CCL2 promotes metastasis and EMT of NSCLC via PI3K/Akt/mTOR axis and autophagy signalling pathways. We believe that CCL2 could be a probable target for the diagnosis and therapeutics of NSCLC, and this study may expand our understanding of lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
- College of Medical Laboratory, Dalian Medical University, Dalian, China.
- Institute of Neurology, Sichuan Academy of Medical Science-Sichuan Provincial Hospital, Medical School of UESTC, Chengdu, China.
ORCID-Profile: Weidong Le
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, H., Wang, J., Al-Nusaif, M., Ma, H., & Le, W. (2024). CCL2 promotes metastasis and epithelial–mesenchymal transition of non‐small cell lung cancer via PI3K /Akt/ mTOR and autophagy pathways. Cell Proliferation, 57(3). https://doi.org/10.1111/cpr.13560
Vancouver
Xu H, Wang J, Al-Nusaif M, Ma H, Le W. CCL2 promotes metastasis and epithelial–mesenchymal transition of non‐small cell lung cancer via PI3K /Akt/ mTOR and autophagy pathways. Cell Proliferation. 2024;57(3). doi:10.1111/cpr.13560
BibTeX
@article{Xu2024,
author = {Xu, Hui and Wang, Jin and Al-Nusaif, Murad and Ma, Huipeng and Le, Weidong},
title = {CCL2 promotes metastasis and epithelial–mesenchymal transition of non‐small cell lung cancer via PI3K /Akt/ mTOR and autophagy pathways},
journal = {Cell Proliferation},
year = {2024},
volume = {57},
number = {3},
doi = {10.1111/cpr.13560}
}
EUVIMED